As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home. This technology is being developed with the aim to reduce rates of infectious diseases, save lives, lower the odds of life-threatening diseases affecting the world’s population, customize patient treatments to increase the odds of success and lower the odds of side-effects as well as to create precise tools for early disease detection. Such a tool has been developed by a molecular genetics diagnostic company is Mainz Biomed N.V. (NASDAQ: MYNZ) that specializes in the early detection of cancer.
Mainz Biomed’s flagship product is the first DNA-based screening test for colorectal cancer in Europe. ColoAlert uses PCR-based molecular genetics testing for specific DNA tumor markers along with proprietary mRNA biomarkers for early CRC and AA detection. It’s not an overstatement to say that with ColoAlert, Mainz Biomed made history for developing this blockbuster test. Mainz Biomed already launched this groundbreaking test in Germany and Romania, the latter of which has the highest CRC incidence rates in Europe. In Romania alone, the potential market for ColoAlert consists of 9.2 million individuals who are aged over 40 and therefore equates to 9.2 million tests per year. Mainz Biomed is also developing a proprietary genetic testing methods for pancreatic cancer which is named PancAlert.
Mainz Biomed CFO Bill Caragol is currently attending JonesTrading 2023 Healthcare Summit which kicked off yesterday and will last until October 11th , 2023 in Miami Beach, Florida. Mainz Biomed will also be presenting the better-than-expected results of its ColoFuture study at the 4th International Conference on Gastroenterology that will be taking place from October 16th to October 18th in Paris. The study that Mainz Biomed conducted involves a multi-center international clinical trial that has assessed the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®.